-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Fate Therapeutics, Lowers Price Target to $2

Benzinga·05/14/2025 14:56:43
Listen to the news
Barclays analyst Peter Lawson maintains Fate Therapeutics (NASDAQ:FATE) with a Overweight and lowers the price target from $10 to $2.